Uncategorized
Kala announces positive results in phase 2 dry eye trial
Kala Pharmaceuticals Inc. announced top-line results in a phase 2 clinical trial of KPI-121 in patients with dry eye disease, the company announced in a press release.According to the release, KPI-121, a novel nanoparticle formulation of loteprednol etabonate that uses Kala's mucus-penetrating particle technology, met its primary sign endpoint in demonstrating statistical superiority of conjunctival hyperemia reduction.